Behavioral health company Acadia Healthcare (NASDAQ:ACHC) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $770.5 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $3.35 billion at the midpoint. Its non-GAAP profit of $0.40 per share was 12% above analysts’ consensus estimates.
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 11.7%. This performance was worse than the S&P 500’s 5.1% loss.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how hospital chains stocks fared in Q4, starting with Acadia Healthcare (NASDAQ:ACHC).
What a brutal six months it’s been for Acadia Healthcare. The stock has dropped 56.9% and now trades at $24.75, rattling many shareholders. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how hospital chains stocks fared in Q4, starting with Tenet Healthcare (NYSE:THC).
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at HCA Healthcare (NYSE:HCA) and its peers.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the hospital chains industry, including Universal Health Services (NYSE:UHS) and its peers.
Shares of behavioral health company Acadia Healthcare (NASDAQ:ACHC)
fell 24.1% in the afternoon session after the company reported weak fourth quarter results: Its revenue guidance for next quarter missed significantly and its EPS fell short of Wall Street's estimates. Overall, this was a softer quarter.
Behavioral health company Acadia Healthcare (NASDAQ:ACHC) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.2% year on year to $774.2 million. Next quarter’s revenue guidance of $770 million underwhelmed, coming in 5.8% below analysts’ estimates. Its non-GAAP profit of $0.64 per share was 10.4% below analysts’ consensus estimates.
